Innovus Pharma Announces the Complete Repayment in
Cash of its Financial Obligations from its
Acquisition of its Beyond Human Assets
Payoff in Cash of Outstanding Secured
Promissory Note with SBI Investments, LLC also
Releases Lien on
Company’s Beyond Human® Assets and the Related
Revenues
Innovus
Pharmaceuticals, Inc. ("Innovus Pharma" or
the “Company”) (OTCQB Venture Market: INNV), an
emerging commercial-stage pharmaceutical company
that delivers safe, innovative and effective
over-the-counter medicine and consumer care products
to improve men’s and women’s health and respiratory
diseases, today announced that it has completed the
repayment in cash of the principal amount of
$550,000 under the 20% Secured Promissory Note,
dated February 19, 2016 (the “Note”) with SBI
Investments, LLC (“SBI”), the financial lender who
financed the Company’s purchase of its Beyond Human®
Sales and Marketing Platform and the nine products
(the “Beyond Human® Products”) that it purchased
from Beyond Human, LLC in March 2016. Pursuant to
its payoff of the Note, SBI has released its
security interest in the Beyond Human® assets and
the revenues generated from those assets.
“We are very proud to
announce that we have repaid in cash all of the
amount we were loaned pursuant to the Note for the
Beyond Human® product portfolio and assets,” stated
Dr. Bassam Damaj, President and Chief Executive
Officer of Innovus Pharma. “The repayment of the
Note in full represents a milestone for the Company
in that pursuant to this pay-off, the security
interest in the Beyond Human® Products and Sales &
Marketing Platform has now been released and all of
the Company’s products and assets are free of any
such interests whatsoever,” he continued.
About Innovus
Pharmaceuticals, Inc.
Headquartered in San
Diego, Innovus Pharma is an emerging OTC consumer
goods and specialty pharmaceutical company engaged
in the commercialization, licensing and development
of safe and effective non-prescription medicine and
consumer care products to improve men’s and women’s
health and vitality and respiratory diseases.
Innovus Pharma delivers innovative and uniquely
presented and packaged health solutions through its
(a) OTC medicines and consumer and health products,
which we market directly, (b) commercial partners to
primary care physicians, urologists, gynecologists
and therapists, and (c) directly to consumers
through our on-line channels, retailers and
wholesalers. The Company is dedicated to be a leader
in developing and marketing new OTC and branded
Abbreviated New Drug Application (“ANDA”) products,
men’s and women’s health supplements, related
diagnostics and medical devices. The Company is
actively pursuing opportunities where existing
prescription drugs have recently, or are expected
to, change from prescription (or Rx) to OTC, as well
as related products.
Emerging Developments: Singlepoint and
Innovus Pharmaceuticals - A Look Ahead into 2018
NEW YORK, NY /
ACCESSWIRE / February 23, 2018 / Latest
key findings by Growth Market Report for all traders,
shareholders, and investors of Singlepoint Inc. (OTCQB:
SING) and Innovus Pharmaceuticals, Inc. (OTCQB:
INNV), including recent technical analysis and
consolidated fundamental information.
Growth Market Report
Initiates Coverage on:
SING DOWNLOAD: http://GrowthMarketReport.com/signup/?co=SING
INNV DOWNLOAD: http://GrowthMarketReport.com/signup/?co=INNV
Singlepoint Inc.
(SING) REPORT OVERVIEW
On February 21st, 2018,
Singlepoint Inc. closed out the trading session at $0.07
(down 3.98%), compared to the previous day close of
$0.0729. The volume on the day was 4,840,244 (down
13.38%), compared to the company's previous day volume
of 5,587,830. Singlepoint is expected to report earnings
on April 6th, 2018, the report will be for the fiscal
period ending December 31st, 2017.
Access Growth Market
Report's Singlepoint Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=SING
Innovus
Pharmaceuticals, Inc. (INNV) REPORT OVERVIEW
On February 21st, 2018,
Innovus Pharmaceuticals, Inc. closed out the trading
session at $0.182 (up 7.06%), compared to the previous
day close of $0.17. The volume on the day was 2,373,792
(up 499.00%), compared to the company's previous day
volume of 396,294. For the twelve months ended December
31st, 2016 vs December 31st, 2015, Innovus
Pharmaceuticals reported revenue of $4.82MM vs $0.74MM
(up 554.97%) and basic earnings per share -$0.15 vs
-$0.08. Innovus Pharmaceuticals is expected to report
earnings on March 5th, 2018, the report will be for the
fiscal period ending December 31st, 2017. The reported
EPS for the same quarter last year was -$0.02. The
estimated EPS forecast for the next fiscal year is $0.00
and is expected to report on March 5th, 2018.
Access Growth Market
Report's Singlepoint Inc. Research Report at:
http://GrowthMarketReport.com/signup/?co=INNV
Our Actionable Research on
Singlepoint Inc. (OTCQB:
SING) and Innovus Pharmaceuticals, Inc. (OTCQB:
INNV) can be downloaded free of charge at http://GrowthMarketReport.com/.
ABOUT Growth Market
Report
It's no
secret that Wall Street analysts spend the lion's share
of their time focused on large, well-known companies and
securities—they make most of their money from investment
banking. As a result, small cap companies are relatively
underserved when it comes to top-quality research and
analysis. Growth Market Report was developed to fill in
that gap.